MS-L6(Agn-PC-0N3ahi, NSC34338) is a potent inhibitor of OXPHOS, targeting electron transport chain complexes I (ETC-I), combining inhibition of NADH oxidation and uncoupling effect, on the respiratory chain. It exhibits potent antitumor efficacy.

MS-L6(Agn-PC-0N3ahi, NSC34338) is a potent inhibitor of OXPHOS, targeting electron transport chain complexes I (ETC-I), combining inhibition of NADH oxidation and uncoupling effect, on the respiratory chain. It exhibits potent antitumor efficacy.

MS-L6(Agn-PC-0N3ahi, NSC34338) is a potent inhibitor of OXPHOS, targeting electron transport chain complexes I (ETC-I), combining inhibition of NADH oxidation and uncoupling effect, on the respiratory chain. It exhibits potent antitumor efficacy.

Etoposide phosphate a phosphate ester proagent of etoposide, is a selective inhibitor of topoisomerase II and a potent anti-cancer chemotherapy agent. Etoposide phosphate also induces cell cycle arrest, apoptosis, and autophagy.

Etoposide phosphate a phosphate ester proagent of etoposide, is a selective inhibitor of topoisomerase II and a potent anti-cancer chemotherapy agent. Etoposide phosphate also induces cell cycle arrest, apoptosis, and autophagy.

Etoposide phosphate a phosphate ester proagent of etoposide, is a selective inhibitor of topoisomerase II and a potent anti-cancer chemotherapy agent. Etoposide phosphate also induces cell cycle arrest, apoptosis, and autophagy.

Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by the zona glomerulosa (ZG) of the adrenal cortex. Aldosterone activity is dependent by the binding and activation of the cytoplasmic/nuclear mineralocorticoid receptor (MR) at cellular level.

Etoposide phosphate a phosphate ester proagent of etoposide, is a selective inhibitor of topoisomerase II and a potent anti-cancer chemotherapy agent. Etoposide phosphate also induces cell cycle arrest, apoptosis, and autophagy.

JAB-3312 is a potent allosteric inhibitor of SHP2 with an IC50 of 1.9 nM and a Kd of 0.37 nM. It is a potential anticancer agent and can be used in cancer research.

JAB-3312 is a potent allosteric inhibitor of SHP2 with an IC50 of 1.9 nM and a Kd of 0.37 nM. It is a potential anticancer agent and can be used in cancer research.